8700万投入失败

动脉网
Sep 26

近期糖尿病研发领域一好一坏两个消息:坏消息是亚宝药业研发的全球首创SGLT1抑制剂SY-009胶囊宣告失败。该药研发历时7年,与礼来共同研发,完成了多项临床研究,但因Ⅱ期临床研究结果疗效终点未达预期,且后续研发投入巨大、存在不确定性而终止,亚宝药业针对SY-009研发投入共计8786.98万元,项目终止将致2025年度利润总额减少超5500万元。此前,亚宝药业与礼来共同研发的另一款SY-008胶囊...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10